Literature DB >> 33572586

The Prognostic Values of PARP-1 Expression in Uveal Melanoma.

Malgorzata Gajdzis1, Stamatios Theocharis2,3, Jerzy Klijanienko3, Nathalie Cassoux4, Sophie Gardrat5, Piotr Donizy6, Radoslaw Kaczmarek1, Pawel Gajdzis3,6.   

Abstract

BACKGROUND: Uveal melanoma is the most common primary intraocular malignancy in adults. In advanced cases, the prognosis is very poor. Thus far, no effective methods of pharmacotherapy of this cancer have been found. The aim of the study was to evaluate the expression of PARP-1, the best-known member of the family of poly(ADP-ribose) polymerases, in uveal melanoma and its associations with clinicopathological parameters, overall survival, and disease-free survival.
METHODS: The study included 91 patients who underwent enucleation due to uveal melanoma. PARP-1 expression was assessed by immunohistochemistry.
RESULTS: High PARP-1 expression was associated with more frequent chromosome 3 loss, higher histopathological grade, bigger tumor size, and absence of intrascleral extension. High PARP-1 expression was associated with shorter overall survival time and disease-free survival time.
CONCLUSIONS: The above findings indicate that high expression of PARP-1 can be considered as an unfavorable prognostic factor in uveal melanoma.

Entities:  

Keywords:  PARP; PARP-1; immunohistochemistry; uveal melanoma

Year:  2021        PMID: 33572586      PMCID: PMC7911114          DOI: 10.3390/cells10020285

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  40 in total

1.  The chromatin scaffold protein SAFB1 renders chromatin permissive for DNA damage signaling.

Authors:  Matthias Altmeyer; Luis Toledo; Thorkell Gudjonsson; Merete Grøfte; Maj-Britt Rask; Claudia Lukas; Vyacheslav Akimov; Blagoy Blagoev; Jiri Bartek; Jiri Lukas
Journal:  Mol Cell       Date:  2013-09-19       Impact factor: 17.970

2.  Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.

Authors:  Elisa Specht; Daniel Kaemmerer; Jörg Sänger; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  Histopathology       Date:  2015-03-23       Impact factor: 5.087

3.  Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Authors:  Bo Yuan; Na Ye; Shan-Shan Song; Yu-Ting Wang; Zilan Song; Hua-Dong Chen; Chuan-Huizi Chen; Xia-Juan Huan; Ying-Qing Wang; Yi Su; Yan-Yan Shen; Yi-Ming Sun; Xin-Ying Yang; Yi Chen; Shi-Yan Guo; Yong Gan; Zhi-Wei Gao; Xiao-Yan Chen; Jian Ding; Jin-Xue He; Ao Zhang; Ze-Hong Miao
Journal:  Cancer Lett       Date:  2016-11-12       Impact factor: 8.679

4.  Altered expression of the poly(ADP-ribosyl)ation enzymes in uveal melanoma and regulation of PARG gene expression by the transcription factor ERM.

Authors:  Vanessa Molloy-Simard; Jean-François St-Laurent; François Vigneault; Manon Gaudreault; Natasha Dargis; Marie-Christine Guérin; Steeve Leclerc; Mohib Morcos; Daniel Black; Yvonne Molgat; Dan Bergeron; Yvan de Launoit; François Boudreau; Serge Desnoyers; Sylvain Guérin
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-14       Impact factor: 4.799

5.  A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation.

Authors:  Gyula Timinszky; Susanne Till; Paul O Hassa; Michael Hothorn; Georg Kustatscher; Bianca Nijmeijer; Julien Colombelli; Matthias Altmeyer; Ernst H K Stelzer; Klaus Scheffzek; Michael O Hottiger; Andreas G Ladurner
Journal:  Nat Struct Mol Biol       Date:  2009-08-13       Impact factor: 15.369

6.  Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1.

Authors:  Dragana Ahel; Zuzana Horejsí; Nicola Wiechens; Sophie E Polo; Elisa Garcia-Wilson; Ivan Ahel; Helen Flynn; Mark Skehel; Stephen C West; Stephen P Jackson; Tom Owen-Hughes; Simon J Boulton
Journal:  Science       Date:  2009-08-06       Impact factor: 47.728

7.  Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue.

Authors:  M Salemi; A Galia; F Fraggetta; C La Corte; P Pepe; S La Vignera; G Improta; P Bosco; A E Calogero
Journal:  Eur J Histochem       Date:  2013-04-15       Impact factor: 3.188

8.  NF-κB signaling mediates acquired resistance after PARP inhibition.

Authors:  Yuko Nakagawa; Anna S Sedukhina; Naoki Okamoto; Satoi Nagasawa; Nao Suzuki; Tomohiko Ohta; Hiroyoshi Hattori; Marta Roche-Molina; Ana J Narváez; Anand D Jeyasekharan; Juan A Bernal; Ko Sato
Journal:  Oncotarget       Date:  2015-02-28

9.  Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.

Authors:  Kyoung Min Kim; Young Jae Moon; See-Hyoung Park; Hye Jeong Park; Sung Il Wang; Ho Sung Park; Ho Lee; Keun Sang Kwon; Woo Sung Moon; Dong Geun Lee; Jung Ryul Kim; Kyu Yun Jang
Journal:  PLoS One       Date:  2016-09-19       Impact factor: 3.240

10.  Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.

Authors:  Piotr Donizy; Cheng-Lin Wu; Jason Mull; Masakazu Fujimoto; Agata Chłopik; Yan Peng; Sara C Shalin; M Angelica Selim; Susana Puig; Maria-Teresa Fernandez-Figueras; Christopher R Shea; Wojciech Biernat; Janusz Ryś; Andrzej Marszalek; Mai P Hoang
Journal:  Cells       Date:  2020-05-05       Impact factor: 6.600

View more
  3 in total

Review 1.  Recent Advances and Challenges in Uveal Melanoma Immunotherapy.

Authors:  Yihang Fu; Wei Xiao; Yuxiang Mao
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia.

Authors:  Alexandros Pergaris; Eugene Danas; Pawel Gajdzis; Georgia Levidou; Malgorzata Gajdzis; Nathalie Cassoux; Sophie Gardrat; Piotr Donizy; Penelope Korkolopoulou; Nikolaos Kavantzas; Jerzy Klijanienko; Stamatios Theocharis
Journal:  Diagnostics (Basel)       Date:  2022-04-19

Review 3.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.